SUPPLEMENTARY MATERIAL

Table S1. Number of rimegepant tablets utilized per month among all treated participantsPage 2
Table S2. Number of days per month using select analgesics or antiemetics
Table S3. List of institutional review boards and ethics committees approving the study protocolPage 7
Figure S1 . Proportion of participants with (A) 100% and (B) 50% reduction in the mean number of days per month using select analgesics following initiation of rimegepant treatmentPage 8
Figure S2. Proportion of participants with (A) 100% and (B) 50% reduction in the mean number of days per month using select antiemetics following initiation of rimegepant treatment

	Rimegepant 75 mg dosing cohort			
	PRN	PRN	EOD+PRN	
Time interval	(2–8) ^a	(9–14) ^b	(4–14) ^c	Overall
Weeks 1–4				
n	1033	481	286	1800
Mean (SD)	4.9 (3.3)	8.5 (4.3)	12.5 (3.4)	7.1 (4.6)
Median	4.0	8.0	13.0	6.0
Weeks 5–8				
Ν	998	452	269	1719
Mean (SD)	5.6 (3.8)	9.2 (4.9)	14.4 (4.0)	7.9 (5.2)
Median	5.0	8.0	15.0	7.0
Weeks 9–12				
n	959	424	251	1634
Mean (SD)	5.7 (4.1)	8.7 (4.9)	14.0 (3.3)	7.7 (5.2)
Median	5.0	8.0	14.0	7.0
Weeks 13–16			•	
N	925	402	-	1460
Mean (SD)	5.5 (3.9)	8.3 (5.2)	_	6.0 (4.5)
Median	5.0	8.0	_	5.0
Weeks 17–20	5.0	0.0		5.0
	889	382		1274
n Moan (SD)			-	
Mean (SD)	5.6 (3.8)	8.3 (5.0)	-	6.4 (4.4)
Median	5.0	8.0	-	6.0
Weeks 21-24	064	250		4000
n N (25)	861	359	-	1220
Mean (SD)	5.7 (4.2)	7.9 (4.8)	-	6.3 (4.5)
Median	5.0	7.0	-	6.0
Weeks 25–28				
n	835	343	-	1178
Mean (SD)	5.6 (4.0)	8.1 (5.0)	-	6.3 (4.5)
Median	5.0	8.0	-	6.0
Weeks 29–32				
n	802	322	-	1124
Mean (SD)	5.6 (4.0)	8.1 (4.9)	-	6.3 (4.4)
Median	5.0	7.0	-	6.0
Weeks 33–36				
n	778	312	-	1090
Mean (SD)	5.7 (4.2)	8.3 (5.1)	-	6.4 (4.6)
Median	5.0	7.5	-	6.0
Weeks 37–40				
n	755	303	-	1058
Mean (SD)	5.7 (4.2)	7.9 (5.1)	-	6.3 (4.6)
Median	5.0	7.0	-	5.0
Weeks 41–44				
VVEEKS 41-44				
n	727	293	-	1020

Table S1. Number of rimegepant tablets utilized per month among all treated participants.

Median	5.0	7.0	-	5.0
Weeks 45–48				
n	711	286	-	997
Mean (SD)	5.8 (4.1)	8.0 (5.4)	-	6.4 (4.6)
Median	5.0	7.0	-	6.0
Weeks 49–52				
n	693	279	-	972
Mean (SD)	5.9 (4.6)	8.1 (5.6)	-	6.5 (5.0)
Median	5.0	7.0	-	5.0

^aPRN dosing (up to 52 weeks) in participants with 2–8 moderate or severe attacks per month in the 3 months prior to screening. ^bPRN dosing (up to 52 weeks) in participants with 9–14 moderate or severe attacks per month in the 3 months prior to screening. ^cEOD+PRN dosing (up to 12 weeks) in participants with 4–14 moderate or severe attacks per month in the 3 months prior to screening. **Abbreviations:** EOD, every other day; PRN, as needed; SD, standard deviation.

	Rimegepant 75 mg dosing cohort				
	PRN	PRN	EOD+PRN		
Time interval	(2–8) ^b	(9–14) ^c	(4–14) ^d	Overall	
Observation period					
n	828	388	225	1441	
No. days, mean (SD)	12.0 (11.1)	14.0 (10.3)	11.6 (10.0)	12.5 (10.7)	
No. days, median	6.0	10.0	7.0	7.0	
Neeks 1–4					
n	828	388	225	1441	
No. days <i>,</i> mean (SD)	8.0 (11.8)	9.2 (11.7)	6.6 (10.6)	8.1 (11.6)	
No. days, median	1.0	3.0	1.0	2.0	
Mean (SD) change	-3.9 (6.4)	-4.7 (6.6)	-5.0 (6.9)	-4.3 (6.6)	
[95% CI]	[-4.4, -3.5]	[-5.4, -4.1]	[-6.0, -4.1]	[-4.7, -4.0]	
P value ^e	<0.0001	<0.0001	<0.0001	<0.0001	
Median change	-2.0	-3.0	-3.0	-2.6	
Weeks 5–8					
n	806	367	216	1389	
No. days, mean (SD)	7.6 (11.8)	8.6 (12.0)	6.1 (10.7)	7.6 (11.7)	
No. days, median	0.0	1.0	0.0	0.0	
Mean (SD) change	-4.3 (6.8)	-5.4 (7.1)	-5.4 (6.9)	-4.7 (6.9)	
[95% CI]	[-4.7, -3.8]	[-6.1, -4.7]	[-6.4, -4.5]	[-5.1, -4.4]	
<i>P</i> value ^e	<0.0001	<0.0001	<0.0001	<0.0001	
Median change	-2.7	-3.5	-4.0	-3.0	
Veeks 9–12					
n	776	346	202	1324	
No. days, mean (SD)	7.4 (11.8)	8.6 (12.1)	5.5 (10.5)	7.4 (11.7)	
No. days, median	0.0	1.0	0.0	0.0	
Mean (SD) change	-4.3 (6.6)	-5.6 (7.2)	-5.8 (6.8)	-4.9 (6.8)	
[95% CI]	[-4.8, -3.9]	[-6.4, -4.8]	[-6.7, -4.8]	[-5.3, -4.5]	
P value ^e	<0.0001	<0.0001	<0.0001	<0.0001	
Median change	-2.7	-3.9	-4.0	-3.0	
Veeks 13–16					
n	751	325	_	1195	
No. days, mean (SD)	7.4 (11.8)	8.2 (12.0)	_	7.4 (11.8)	
No. days, median	0.0	0.0	_	0.0	
Mean (SD) change	-4.3 (6.5)	-5.6 (6.9)	_	-4.9 (6.8)	
[95% CI]	[-4.8, -3.9]	[-6.4, -4.9]	_	[-5.2, -4.5]	
P value ^e	<0.0001	<0.0001	_	<0.0001	
Median change	-2.7	-4.0	-	-3.0	
Veeks 17–20					
n	724	309	-	1035	
No. days, mean (SD)	7.5 (11.9)	8.3 (12.1)	-	7.7 (12.0)	
No. days, median	0.0	0.0	-	0.0	
Mean (SD) change	-4.2 (6.7)	-5.6 (7.0)	-	-4.6 (6.8)	
[95% CI]	[-4.7, -3.7]	[-6.3, -4.8]	-	[-5.0, -4.2]	
<i>P</i> value ^e	<0.0001	<0.0001	-	< 0.0001	
		·			

Median change	-2.7	-4.0	_	-3.0
Weeks 21–24				
n	699	289	-	988
No. days <i>,</i> mean (SD)	7.4 (11.9)	8.4 (12.2)	-	7.7 (12.0)
No. days, median	0.0	0.0	-	0.0
Mean (SD) change	-4.3 (6.5)	-5.6 (6.8)	_	-4.7 (6.6)
[95% CI]	[-4.8, -3.8]	[-6.4, -4.8]	_	[-5.1, -4.3]
<i>P</i> value ^e	<0.0001	<0.0001	_	<0.0001
Median change	-2.7	-4.0	_	-3.0
Weeks 25–28				
n	679	277	_	956
No. days <i>,</i> mean (SD)	7.2 (11.8)	8.2 (12.2)	_	7.5 (11.9)
No. days, median	0.0	0.0	-	0.0
Mean (SD) change	-4.4 (6.6)	-5.5 (6.6)	_	-4.7 (6.6)
[95% CI]	[-4.9, -3.9]	[-6.3, -4.7]	_	[-5.1, -4.3]
P value ^e	<0.0001	<0.0001	_	<0.0001
Median change	-2.9	-4.1	_	-3.0
Weeks 29–32				
n	653	261	_	914
No. days, mean (SD)	7.4 (11.9)	8.3 (12.3)	_	7.6 (12.0)
No. days, median	0.0	0.0	_	0.0
Mean (SD) change	-4.3 (6.7)	-5.4 (6.5)	_	-4.6 (6.7)
[95% CI]	[-4.8, -3.8]	[-6.2, -4.6]	_	[-5.0, -4.2]
<i>P</i> value ^e	<0.0001	<0.0001	_	<0.0001
Median change	-2.8	-4.0	_	-3.0
Weeks 33–36				
n	631	253	_	884
No. days, mean (SD)	7.5 (11.9)	8.1 (12.2)	_	7.6 (12.0)
No. days, median	0.0	0.0	_	0.0
Mean (SD) change	-4.2 (6.9)	-5.4 (6.4)	_	-4.5 (6.8)
[95% CI]	[-4.7, -3.6]	[-6.2, -4.7]	_	[-5.0, -4.1]
<i>P</i> value ^e	<0.0001	<0.0001	_	<0.0001
Median change	-2.8	-4.0	_	-2.9
Weeks 37–40				
n	612	246	_	858
No. days, mean (SD)	7.3 (11.9)	8.0 (12.1)	_	7.5 (12.0)
No. days, median	0.0	0.0	_	0.0
Mean (SD) change	-4.4 (6.7)	-5.5 (6.6)	_	-4.7 (6.7)
[95% CI]	[-5.0, -3.9]	[-6.3, -4.7]	_	[-5.2, -4.3]
<i>P</i> value ^e	<0.0001	<0.0001	_	<0.0001
Median change	-2.9	-4.0	_	-3.0
Weeks 41–44	2.5			5.0
n	589	235	_	824
		7.8 (12.1)	_	7.5 (11.9)
No days mean (SD)	7 3 (11 9)			, .J (±±.J)
No. days, mean (SD) No. days. median	7.3 (11.9) 0.0		_	• •
No. days, median	0.0	0.0	-	0.0
No. days, median Mean (SD) change	0.0 -4.3 (6.6)	0.0 -5.5 (6.4)	-	0.0 -4.7 (6.6)
No. days, median	0.0	0.0	- - -	0.0

Median change	-2.8	-4.0	-	-3.0
Weeks 45–48				
n	577	228	_	805
No. days, mean (SD)	7.2 (11.8)	8.0 (12.1)	_	7.4 (11.9)
No. days, median	0.0	0.0	_	0.0
Mean (SD) change	-4.3 (6.4)	-5.4 (6.6)	_	-4.6 (6.4)
[95% CI]	[-4.9 <i>,</i> -3.8]	[-6.3, -4.6]	_	[-5.1, -4.2]
<i>P</i> value ^e	< 0.0001	<0.0001	_	<0.0001
Median change	-2.9	-4.0	_	-3.0
Weeks 49–52				
n	560	225	_	785
No. days, mean (SD)	7.2 (11.9)	8.0 (12.1)	_	7.5 (11.9)
No. days, median	0.0	0.0	_	0.0
Mean (SD) change	-4.3 (6.5)	-5.4 (6.5)	_	-4.7 (6.5)
[95% CI]	[-4.9, -3.8]	[-6.3, -4.6]	_	[-5.1, -4.2]
<i>P</i> value ^e	<0.0001	<0.0001	_	<0.0001
Median change	-2.9	-4.2	-	-3.0

^aAmong participants using analgesics or antiemetics during the observation period: PRN (2–8), n = 828; PRN (9–14), n = 388; EOD + PRN (4–14), n = 225; Overall, n= 1441. Number of drug days per 4 weeks is prorated to 28 days in the (1) observation period and (2) last time interval for participants with <28 study days in their last time interval.


^bPRN dosing (up to 52 weeks) in participants with 2–8 moderate or severe attacks per month in the 3 months prior to screening. ^cPRN dosing (up to 52 weeks) in participants with 9–14 moderate or severe attacks per month in the 3 months prior to screening. ^dEOD+PRN dosing (up to 12 weeks) in participants with 4–14 moderate or severe attacks per month in the 3 months prior to screening. ^eP value is relative to the observation period.

Abbreviations: CI, confidence interval; EOD, every other day; PRN, as needed; SD, standard deviation.


Table S3. List of institutional review boards and ethics committees approving the study protocol.

Schulman Associates IRB 44445 Lake Forest Drive Suite 300 Cincinnati, OH 45242 United States of America Advarra IRB 6940 Columbia Gateway Drive Suite 110 Columbia, MD 21046 Biomedical Research Allliance of New York, LLC. IRB 1981 Marcus Avenue Suite 210 Lake Success, NY 11042 United States of America

Figure S1. Proportion of participants with (A) 100% and (B) 50% reduction in the mean number of days per month using select analgesics following initiation of rimegepant treatment.^a




B. 50% reduction



^aAmong participants using analgesics during the observation period:
PRN (2–8), n = 814; PRN (9–14), n = 379; EOD + PRN (4–14), n = 222; Overall, n = 1415. Confidence intervals were calculated using the Agresti-Coull method. **Abbreviations:** CI, confidence interval; EOD, every other day; PRN, as needed.

Figure S2. Proportion of participants with (A) 100% and (B) 50% reduction in the mean number of days per month using select antiemetics following initiation of rimegepant treatment.^a



^aAmong participants using antiemetics during the observation period:
PRN (2–8), n = 52; PRN (9–14), n = 40; EOD + PRN (4–14), n = 14; Overall, n = 106.
Confidence intervals were calculated using the Agresti-Coull method.
Abbreviations: CI, confidence interval; EOD, every other day; PRN, as needed.